Preventing Falls Through Enhanced Pharmaceutical Care

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Susan Blalock, PhD, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT00618800
First received: February 7, 2008
Last updated: September 16, 2011
Last verified: September 2011

February 7, 2008
September 16, 2011
August 2004
September 2008   (final data collection date for primary outcome measure)
  • Time to first fall [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Proportion of participants who fall [ Time Frame: One Year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00618800 on ClinicalTrials.gov Archive Site
Use of high-risk medications [ Time Frame: One Year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Preventing Falls Through Enhanced Pharmaceutical Care
Preventing Falls Through Enhanced Pharmaceutical Care

The objective of the proposed study is to reduce the incidence of falls and fall-related injuries among community-dwelling older adults by better utilizing community pharmacists to advise patients and physicians on medication management.

Falls are the leading cause of both fatal and nonfatal injuries among older adults in the United States. Past research suggests that individuals taking four or more prescription medications are at increased risk for falls. CNS-active drugs (e.g., benzodiazepines), in particular, have been associated with increased risk. Research also suggests that interventions to reduce inappropriate medications can reduce the risk of falls. This finding comes primarily from multifaceted interventions, however, and the impact of medication modification, by itself, remains largely unknown.

This study is using a a randomized controlled clinical trial design to evaluate a falls prevention program targeting community-dwelling older adults through community pharmacies. The study focuses on individuals at high risk for future falls. Individuals in the intervention group receive an in-depth consultation concerning their current medications, conducted by a community pharmacist. The consultation is designed to elicit medication-related problems (e.g., orthostatic hypotension, daytime sedation). Problems identified during the consultation, and therapeutic recommendations designed to address these problems, are communicated to the prescribing physician. With physician approval, appropriate modifications are made to the patient's medication regimen. The primary study endpoints are: time to first fall and proportion of individuals who fall during the one-year follow-up period.

Two primary hypotheses will be tested.

  1. Compared to individuals in the control group, individuals in the intervention group will experience a 30% reduction in the hazard of falling (hazard ratio=0.70) for time to first fall following randomization.
  2. Compared to individuals in the control group, 25% fewer people in the intervention group will experience a fall during the one-year follow-up period.

If the intervention is effective in reducing falls, these effects should be mediated by improvements in the overall quality of medication use. Thus, we will also assess effects of the intervention on: change in the number of inappropriate medications prescribed and change in the number of CNS-active medications prescribed.

One secondary hypotheses will be tested.

1. Compared to individuals in the control group, individuals in the intervention group will experience a 40% reduction in the use of high-risk medications during the one-year follow-up period.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Falls
  • Behavioral: Pharmaceutical Care
    Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
  • Other: Written Materials
    Participants receive written information about falls prevention.
  • Experimental: Pharmacist Care
    Pharmacist Intervention
    Intervention: Behavioral: Pharmaceutical Care
  • Active Comparator: Control
    Written information only group
    Intervention: Other: Written Materials
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
September 2009
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Currently taking at least four prescription medications
  • Currently taking at least one high risk medication
  • At least one fall during 12 month period before study entry
  • Able to speak and read English

Exclusion Criteria:

  • Resident of a long-term care facility
  • Cognitive impairment
  • Housebound
Both
65 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00618800
5-38047/0-401-4974
No
Susan Blalock, PhD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
Not Provided
Principal Investigator: Susan J. Blalock, PhD University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP